| scholarly article | Q13442814 |
| P50 | author | Kathleen A. Shutt | Q39920417 |
| William Schaffner | Q66126603 | ||
| Cynthia G Whitney | Q90408422 | ||
| Bernard Beall | Q91693421 | ||
| Monica M Farley | Q106358785 | ||
| Nancy M Bennett | Q106358857 | ||
| Lee H Harrison | Q106360777 | ||
| Susan Petit | Q106360902 | ||
| Arthur Reingold | Q111077191 | ||
| Catherine A Lexau | Q114413532 | ||
| P2093 | author name string | Ann Thomas | |
| Matthew R Moore | |||
| James H Jorgensen | |||
| Heather E Hsu | |||
| Allen S Craig | |||
| P2860 | cites work | Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine | Q22250891 |
| Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study | Q28270868 | ||
| Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine | Q28306783 | ||
| Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis | Q29011885 | ||
| Practice guidelines for the management of bacterial meningitis | Q33982444 | ||
| Bacterial meningitis in the United States in 1995. Active Surveillance Team | Q34448928 | ||
| Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. | Q40166390 | ||
| Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae | Q41831877 | ||
| ??? | Q28142317 | ||
| Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine | Q44408877 | ||
| Penicillin-resistant pneumococcal meningitis: high antibiotic exposure impedes new vaccine protection. | Q44795044 | ||
| Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q44980590 | ||
| Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections | Q46780912 | ||
| Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation | Q46865400 | ||
| Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. | Q50739879 | ||
| Clonal Relationships between Invasive and Carriage Streptococcus pneumoniae and Serotype‐ and Clone‐Specific Differences in Invasive Disease Potential | Q59538910 | ||
| Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae | Q64130946 | ||
| Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization | Q64131295 | ||
| Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants | Q73070103 | ||
| Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers | Q73509127 | ||
| Bacterial meningitis in childhood at the Children's Hospital of Pittsburgh: 1988-1998 | Q77394668 | ||
| Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine | Q80543770 | ||
| Changing epidemiology of bacterial meningitis | Q80585599 | ||
| Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003 | Q81216904 | ||
| Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine | Q81402633 | ||
| Pneumococcal vaccine--direct and indirect ("herd") effects | Q83103217 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meningitis | Q48143 |
| vaccine | Q134808 | ||
| pneumococcal meningitis | Q3854685 | ||
| pneumococcal conjugate vaccine | Q7205991 | ||
| P304 | page(s) | 244-256 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Effect of pneumococcal conjugate vaccine on pneumococcal meningitis | |
| P478 | volume | 360 |
| Q38246355 | 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children |
| Q38137006 | 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents |
| Q35969430 | A Pneumococcal Carriage Study in Danish Pre-school Children before the Introduction of Pneumococcal Conjugate Vaccination. |
| Q51900977 | A Public Health Perspective on Cochlear Implants and Meningitis in Children |
| Q26753152 | A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens |
| Q37483596 | A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). |
| Q34056914 | A novel protein, RafX, is important for common cell wall polysaccharide biosynthesis in Streptococcus pneumoniae: implications for bacterial virulence |
| Q58587115 | A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13 |
| Q37187296 | A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis |
| Q34616438 | Acute bacterial meningitis in infants and children |
| Q49693480 | Adult Patients with Pneumococcal Meningitis at a Neurosurgical Neurologic Center: Different Predisposing Conditions? |
| Q38058958 | Advances in treatment of bacterial meningitis |
| Q33530554 | African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults |
| Q84729221 | An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups |
| Q37668036 | Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development |
| Q47108789 | Antigenic Variation and Immune Escape in the MTBC. |
| Q35976434 | Applying the bacterial meningitis score in children with cerebrospinal fluid pleocytosis: a single center's experience. |
| Q34792516 | Bacterial Meningitis in Brazil: Baseline Epidemiologic Assessment of the Decade Prior to the Introduction of Pneumococcal and Meningococcal Vaccines |
| Q34224472 | Bacterial causes of empyema in children, Australia, 2007-2009. |
| Q63367687 | Bacterial meningitis |
| Q38673529 | Bacterial meningitis in Finland, 1995-2014: a population-based observational study |
| Q38130726 | Bacterial meningitis in children in Iceland, 1975-2010: a nationwide epidemiological study |
| Q38117051 | Bacterial meningitis in older adults |
| Q84104165 | Bacterial meningitis vaccines: not just for kids |
| Q38570487 | Bacterial meningitis: an update of new treatment options |
| Q84959588 | Bacterial meningitis: epidemiology, pathogenesis and management update |
| Q38145360 | Bacterial meningitis: new therapeutic approaches |
| Q34562726 | Bexsero® chronicle |
| Q33816288 | Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013. |
| Q36667552 | Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales |
| Q34596707 | Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States |
| Q90571113 | Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: Emergence of drug-resistant non-vaccine serotypes |
| Q38485854 | Changing etiology of community-acquired bacterial meningitis in adults: a nationwide multicenter study in Korea. |
| Q96607557 | Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections |
| Q34637890 | Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives |
| Q40176226 | Childhood Deaths Attributable to Invasive Pneumococcal Disease in England and Wales, 2006-2014. |
| Q41865508 | Clinical characteristics of streptococcus pneumoniae meningoencephalitis after transsphenoidal surgery: three case reports |
| Q35694016 | Clinical features and outcomes of invasive pneumococcal disease in a pediatric intensive care unit |
| Q26851961 | Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance |
| Q62658768 | Cochrane Review: Immunostimulants for preventing respiratory tract infection in children |
| Q43568749 | Community-acquired bacterial meningitis |
| Q39422232 | Comparative impact of pneumococcal conjugate vaccines on pneumococcal meningitis according to underlying conditions |
| Q40185812 | Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies |
| Q39756501 | Complete Genome Sequence of Streptococcus pneumoniae Serotype 19A, a Blood Clinical Isolate from Northeast Mexico |
| Q30406750 | Contribution of vaccines to our understanding of pneumococcal disease |
| Q82461835 | Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina |
| Q37559623 | Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine |
| Q43975432 | Declining invasive pneumococcal disease mortality in the United States, 1990-2005. |
| Q34663993 | Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas |
| Q35914703 | Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP) |
| Q90461757 | Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection |
| Q34316015 | Development of Streptococcus pneumoniae Vaccines Using Live Vectors |
| Q26799527 | Dissecting the indirect effects caused by vaccines into the basic elements |
| Q40501244 | Draft Genome Sequence of an Atypical Strain of Streptococcus pneumoniae Serotype 19A Isolated from Cerebrospinal Fluid |
| Q33551026 | Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease |
| Q40856734 | Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children |
| Q45762661 | Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme |
| Q43642775 | Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan |
| Q92812003 | Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000-June 30, 2016 |
| Q64916083 | Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. |
| Q58550643 | Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010-2017 |
| Q34194058 | Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands |
| Q37864327 | Emerging drugs for pneumococcal pneumonia |
| Q35619025 | Emerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitro |
| Q34087265 | Enhanced determination of Streptococcus pneumoniae serotypes associated with invasive disease in Laos by using a real-time polymerase chain reaction serotyping assay with cerebrospinal fluid |
| Q38079159 | Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines. |
| Q46049809 | Epidemiological analysis on two decades of hospitalisations for meningitis in the United States |
| Q33648635 | Epidemiological profile of meningococcal disease in the United States |
| Q42202691 | Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study |
| Q30431534 | Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis |
| Q43903386 | Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States |
| Q42248845 | Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain |
| Q42871994 | Evaluation of pneumococcal serotyping by multiplex PCR and quellung reactions |
| Q37729284 | Factors That Negatively Affect the Prognosis of Pediatric Community-Acquired Pneumonia in District Hospital in Tanzania. |
| Q33798133 | Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010. |
| Q58286147 | Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children |
| Q35783402 | Frequency of Pathogenic Paediatric Bacterial Meningitis in Mozambique: The Critical Role of Multiplex Real-Time Polymerase Chain Reaction to Estimate the Burden of Disease |
| Q29248091 | From the microbiome to the central nervous system, an update on the epidemiology and pathogenesis of bacterial meningitis in childhood |
| Q37837477 | From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease |
| Q38011321 | Future challenges in the elimination of bacterial meningitis |
| Q34310321 | GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis |
| Q38099207 | Genome-based bacterial vaccines: current state and future outlook. |
| Q36307701 | Genome-wide analysis of a avirulent and reveal the strain induces pro-tective immunity against challenge with virulent Streptococcus suis Serotype 2. |
| Q44677055 | Global epidemiology of meningococcal disease. |
| Q37821484 | Global prevailing and emerging pediatric pneumococcal serotypes |
| Q37649380 | Guidelines for the management of suspected and confirmed bacterial meningitis in Canadian children older than one month of age. |
| Q35864174 | Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis |
| Q35319990 | Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study. |
| Q30382878 | Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults. |
| Q44961893 | Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). |
| Q35201246 | Identification of the serotypes of bacterial meningitis agents; implication for vaccine usage |
| Q35874108 | Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination |
| Q89080565 | Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae |
| Q36962721 | Immunosenescence and novel vaccination strategies for the elderly. |
| Q24243914 | Immunostimulants for preventing respiratory tract infection in children |
| Q41247311 | Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil |
| Q38677563 | Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children |
| Q40131358 | Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. |
| Q51363718 | Impact of pneumococcal conjugate vaccine on pediatric tympanostomy tube insertion in partial immunized population. |
| Q93346064 | Impact of pneumococcal conjugate vaccines introduction on antibiotic resistance of Streptococcus pneumoniae meningitis in children aged 5 years or younger, Israel, 2004 to 2016 |
| Q36229752 | Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. |
| Q40942223 | Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children |
| Q34682074 | Impact of the lab-score on antibiotic prescription rate in children with fever without source: a randomized controlled trial |
| Q34587235 | In-hospital management of children with bacterial meningitis in Italy |
| Q57165215 | Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey |
| Q33952107 | Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil. |
| Q85167912 | Infectious disease: do steroids benefit patients with bacterial meningitis? |
| Q37335485 | Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine |
| Q44828647 | Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience |
| Q34388781 | Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306. |
| Q37982359 | Invasive pneumococcal disease in infants younger than 60 days |
| Q38678793 | Invasive pneumococcal infection despite 7-valent conjugated vaccine |
| Q51138353 | Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009. |
| Q51193414 | Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates. |
| Q46122731 | Lignes directrices pour la prise en charge de la méningite bactérienne présumée ou confirmée chez les enfants canadiens de plus d’un mois |
| Q38437227 | Mechanisms and impact of genetic recombination in the evolution of Streptococcus pneumoniae |
| Q26770696 | Meningococcal B vaccine and the vision of a meningitis free world |
| Q34554521 | Methods of rapid diagnosis for the etiology of meningitis in adults |
| Q37252358 | Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A |
| Q30498477 | Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema |
| Q36826926 | Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae |
| Q85068604 | Nasopharyngeal Carriage of Individual Streptococcus pneumoniae Serotypes During Pediatric Pneumonia as a Means to Estimate Serotype Disease Potential |
| Q36153943 | Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines |
| Q89593636 | New Strategy Is Needed to Prevent Pneumococcal Meningitis |
| Q35028495 | Next generation pneumococcal vaccines |
| Q37844538 | Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination |
| Q33909187 | Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine |
| Q34516718 | Parental decline of pneumococcal vaccination and risk of pneumococcal related disease in children |
| Q27027234 | Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion |
| Q24628983 | Pathophysiology and treatment of bacterial meningitis |
| Q38871666 | Pediatric Acute Otitis Media in the Era of Pneumococcal Vaccination |
| Q36156085 | Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines |
| Q34077277 | Pertussis in Florida, 2000–2006: Trends in a Historically Low-Incidence State |
| Q50167719 | Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). |
| Q38068919 | Pharmacotherapy for pneumococcal infections: an update |
| Q60313538 | Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009-June 2015 |
| Q33772409 | Pneumococcal Vaccination Strategies. An Update and Perspective. |
| Q26798168 | Pneumococcal disease and use of pneumococcal vaccines in Taiwan |
| Q37736653 | Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development |
| Q30406799 | Pneumococcal disease manifestation in children before and after vaccination: what's new? |
| Q35105368 | Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany |
| Q37422587 | Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah |
| Q84633414 | Pneumococcal meningitis still with us in the era of conjugate vaccines |
| Q37965672 | Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13(®)]: profile report |
| Q37794965 | Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. |
| Q43088234 | Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). |
| Q41519208 | Pneumococcal wall teichoic acid is required for the pathogenesis of Streptococcus pneumoniae in murine models |
| Q33940163 | Pneumonia and poverty: a prospective population-based study among children in Brazil |
| Q34746162 | Poor adherence to antibiotic prescribing guidelines in acute otitis media--obstacles, implications, and possible solutions |
| Q33729202 | Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005 |
| Q37699644 | Post-licensure monitoring of HPV vaccine in the United States |
| Q24200590 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q24242705 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q38726046 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q38255287 | Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough |
| Q83633048 | Prevalence of pneumococcal serotypes and resistance to antimicrobial agents in patients with meningitis: ten-year analysis |
| Q50992672 | Prevention of pneumococcal disease through vaccination. |
| Q37191236 | Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide |
| Q34618641 | PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan |
| Q59692140 | Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States |
| Q36210595 | Racial and Regional Differences in Rates of Invasive Pneumococcal Disease |
| Q33965380 | Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. |
| Q33533300 | Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease |
| Q41617785 | Recent trends in epidemiology of invasive pneumococcal disease in Poland. |
| Q39983387 | Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany |
| Q90744431 | Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: A need to expand vaccination policy? |
| Q36276795 | Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008 |
| Q33494765 | Self-reported pediatricians' management of the well-appearing young child with fever without a source: first survey in an European country in the anti-pneumococcal vaccine era. |
| Q37682905 | Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. |
| Q48183164 | Serotype 35B Pneumococcal Meningitis in an Infant: Effect of Conjugate Vaccines on Invasive Disease and Implications for Practice |
| Q36212036 | Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013. |
| Q93035712 | Serotype Distribution and Antimicrobial Resistance of Invasive and Noninvasive Streptococcus pneumoniae Isolates in Korea between 2014 and 2016 |
| Q36172438 | Serotype and clonal evolution of penicillin-nonsusceptible invasive Streptococcus pneumoniae in the 7-valent pneumococcal conjugate vaccine era in Italy |
| Q40643836 | Serotype distribution and penicillin-non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines |
| Q83884218 | Serotype replacement after pneumococcal vaccination |
| Q38069943 | Serotype-independent pneumococcal vaccines. |
| Q35004396 | Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites |
| Q92149546 | Spatial analysis of pneumococcal meningitis in São Paulo in the pre- and post-immunization era |
| Q41812892 | Streptococcus pneumoniae NanC: STRUCTURAL INSIGHTS INTO THE SPECIFICITY AND MECHANISM OF A SIALIDASE THAT PRODUCES A SIALIDASE INHIBITOR. |
| Q33886611 | Streptococcus pneumoniae clonal complex 199: genetic diversity and tissue-specific virulence |
| Q35569198 | Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine. |
| Q31063000 | Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010. |
| Q35096385 | Streptococcus pneumoniae serotype 6C: an intra- and interclonal complex comparison. |
| Q34215330 | Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function |
| Q57195018 | Stroke in paediatric pneumococcal meningitis: a cross-sectional population-based study |
| Q37613925 | Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization |
| Q92364779 | Targeting the complement system in bacterial meningitis |
| Q37782292 | The Impact of Vaccination on Rhinosinusitis and Otitis Media |
| Q91889973 | The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA |
| Q40851776 | The aetiology of paediatric bloodstream infections changes after pneumococcal vaccination and group B streptococcus prophylaxis |
| Q50355979 | The burden of pneumococcal meningitis in Austrian children between 2001 and 2008. |
| Q33879697 | The causative organisms of bacterial meningitis in Korean children in 1996-2005. |
| Q37192158 | The changing epidemiology of childhood pneumococcal disease in Korea |
| Q35822877 | The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. |
| Q58286304 | The current status of invasive pneumococcal disease in Poland |
| Q42131377 | The development of an experimental multiple serogroups vaccine for Neisseria meningitidis |
| Q39707818 | The future of pneumococcal disease prevention |
| Q64892500 | The impact of childhood pneumococcal vaccination on hospital admissions in England: a whole population observational study. |
| Q37928176 | The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America |
| Q84817240 | The potential cost-effectiveness of infant pneumococcal vaccines in Australia |
| Q40332317 | The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis |
| Q87499178 | The relevance of pneumococcal serotypes |
| Q43554420 | The spectrum of pneumococcal empyema in adults in the early 21st century |
| Q42751542 | Treatment of Drug-resistant Pneumococcal Meningitis |
| Q37483938 | Treatment strategies for central nervous system infections |
| Q47917014 | Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States. |
| Q36845343 | Usefulness of inflammatory biomarkers in discriminating between bacterial and aseptic meningitis in hospitalized children from a population with low vaccination coverage. |
| Q84336201 | Vaccine discovery and translation of new vaccine technology |
| Q38538836 | Vaccines for prevention of group B meningococcal disease: Not your father's vaccines |
| Q82502316 | What do the next 100 years hold for pneumococcal vaccination? |
Search more.